DalsnaFinance

Atyr Pharma Inc $ATYR

Health Care

California
Create a scorecard

Live price temporarily unavailable.

Price history
Loading chart…

Atyr Pharma Inc (ATYR) is a Health Care company. Latest news and coverage below.

IPO: May 7, 2015 · $14.00 offering · NASDAQ · View IPO details →

Atyr Pharma Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$10.5M−$31.8M−$74.1MFY2016 net income: −$57.9M'16FY2017 net income: −$48.2M'17FY2018 net income: −$34.5M'18FY2019 revenue: $422.0KFY2019 net income: −$16.2M · Net margin −3844.5%'19FY2020 revenue: $10.5MFY2020 net income: −$16.2M · Net margin −155.2%'20FY2021 revenue: $0FY2021 net income: −$33.8M'21FY2022 revenue: $10.4MFY2022 net income: −$45.3M · Net margin −436.5%'22FY2023 revenue: $353.0KFY2023 net income: −$50.4M · Net margin −14274.5%'23FY2024 revenue: $235.0KFY2024 net income: −$64.0M · Net margin −27243.8%'24FY2025 revenue: $190.0KFY2025 net income: −$74.1M · Net margin −39009.5%'25−100%−75%−50%−25%0%FY2019 net margin: −3844.5% (off the scale, which stops at −100.0%)FY2020 net margin: −155.2% (off the scale, which stops at −100.0%)FY2022 net margin: −436.5% (off the scale, which stops at −100.0%)FY2023 net margin: −14274.5% (off the scale, which stops at −100.0%)FY2024 net margin: −27243.8% (off the scale, which stops at −100.0%)FY2025 net margin: −39009.5% (off the scale, which stops at −100.0%)
Atyr Pharma Inc annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue———$422.0K$10.5M$0$10.4M$353.0K$235.0K$190.0K
Growth (year over year)————+2377.5%−100.0%—−96.6%−33.4%−19.1%
Operating income−$57.9M−$47.1M−$32.8M−$23.0M−$15.9M−$34.0M−$46.4M−$54.9M−$67.9M−$77.6M
Operating margin———−5445.0%−152.2%—−446.8%−15557.8%−28899.6%−40856.3%
Net income−$57.9M−$48.2M−$34.5M−$16.2M−$16.2M−$33.8M−$45.3M−$50.4M−$64.0M−$74.1M
Net margin———−3844.5%−155.2%—−436.5%−14274.5%−27243.8%−39009.5%
EPS (diluted)−$2.44−$26.13−$16.11−$7.03−$1.77−$1.77−$1.60−$0.94−$0.86−$0.80
Balance sheet
Cash and equivalents$38.4M$21.1M$23.0M$9.21M$17.0M$2.34M$9.98M$22.5M$11.1M$10.7M
Total assets$80.5M$89.4M$52.7M$36.2M$38.7M$115.5M$95.8M$120.7M$96.8M$93.0M
Total liabilities$17.7M$25.1M$19.1M$15.2M$7.24M$6.41M$24.5M$30.2M$27.0M$25.7M
Long-term debt$9.20M$14.7M$8.26M———————
Shareholders' equity$62.8M$64.2M$33.6M$21.2M$31.6M$109.3M$71.5M$90.7M$70.0M$67.5M
Cash flow
Operating cash flow−$52.9M−$42.4M−$31.1M−$20.0M−$15.3M−$33.1M−$41.9M−$33.2M−$69.1M−$62.0M
Capital expenditure$600.0K$1.31M$594.0K$79.0K$202.0K$192.0K$1.64M$4.21M$65.0K$77.0K
Free cash flow−$53.5M−$43.7M−$31.7M−$20.1M−$15.5M−$33.3M−$43.5M−$37.4M−$69.2M−$62.1M

From Atyr Pharma Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →

About Atyr Pharma Inc

Headquarters
San Diego, California From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →